CORONAVIRUSPublished 1 hour ago
Experimental coronavirus treatment leronlimab has delivered 'impressive' early results, developer says
By James Rogers | Fox News
Facebook
Twitter
Flipboard
Comments
Print
Email
Harvard study finds US needs to triple current testing for coronavirusVideo
Harvard study finds US needs to triple current testing for coronavirus
Reaction and analysis from Harvard Global Health Institute's Dr. Ashish Jha on ‘America’s News HQ.’
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.
The experimental coronavirus treatment leronlimab has reduced the plasma viral load and restored the immune system of COVID-19 patients, according to data from a small group of patients.
“The results are impressive,” said Nader Pourhassan, the CEO of biotech firm CytoDyn during a conference call Monday.
Leronlimab is a viral-entry inhibitor that has targeted HIV and breast cancer. The drug also has been attracting attention as a potential coronavirus treatment, particularly to quell the so-called “cytokine storm,” when COVID-19 has caused the immune system to go awry.
“Leronlimab decreases plasma viral load,” said Dr. Bruce Patterson, the CEO of diagnostic specialist IncellDX during the conference call, noting that leronlimab also restored immune cells.
Patterson said his lab performed a blood-sample analysis of the first 10 COVID-19 patients enrolled in Emergency Investigational New Drug treatments at Montefiore Medical Center.
“That is remarkable for one drug to restore the immune system and decrease the viral burden in these patients,” Patterson added. “That is what gives us great hope and great excitement about leronlimab going forward in these trials.”
CytoDyn has been enrolling patients in two clinical trials for COVID-19: a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 patients in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 patients in several hospitals throughout the country, company executives said in a statement.
Leronlimab has been one of multiple drugs in the spotlight as the world scrambled to contain the coronavirus pandemic. Many experts, however, have warned that people should not take drugs unless a doctor prescribes them.
CytoDyn recently announced leronlimab had shown a “very promising” response in COVID-19 patients with mild-to-moderate symptoms.
